{
    "clinical_study": {
        "@rank": "136419", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die. Combining more than one drug may kill more tumor cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating\n      patients who have metastatic colorectal cancer."
        }, 
        "brief_title": "Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer", 
        "completion_date": {
            "#text": "November 2003", 
            "@type": "Actual"
        }, 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the response rate of patients with metastatic colorectal carcinoma treated\n           with O6-benzylguanine and carmustine.\n\n        -  Evaluate tumor tissue biochemical and immunohistochemical predictors of response in\n           patients treated with this regimen.\n\n        -  Correlate carcinoembryonic antigen levels in the peripheral blood with response in\n           patients treated with this regimen.\n\n      OUTLINE: This is a multicenter study.\n\n      Patients receive O6-benzylguanine (BG) IV over 1 hour and carmustine IV over 1 hour\n      (beginning 1 hour after completion of BG infusion) on day 1. Treatment continues every 6\n      weeks in the absence of disease progression or unacceptable toxicity.\n\n      Patients are followed every 3 months.\n\n      PROJECTED ACCRUAL: A total of 19-36 patients will be accrued for this study within 1.7-3\n      years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Diagnosis of metastatic colorectal carcinoma\n\n          -  Bidimensionally measurable disease\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  ECOG 0-2\n\n        Life expectancy:\n\n          -  At least 12 weeks\n\n        Hematopoietic:\n\n          -  WBC at least 4,000/mm^3\n\n          -  Granulocyte count at least 1,500/mm^3\n\n          -  Absolute neutrophil count at least 1,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n          -  Hemoglobin greater than 8 g/dL\n\n        Hepatic:\n\n          -  Bilirubin no greater than 1.2 mg/dL\n\n          -  AST and ALT less than 2.5 times upper limit of normal (ULN)\n\n          -  PT no greater than ULN (not on anticoagulation therapy)\n\n        Renal:\n\n          -  Creatinine no greater than 1.5 mg/dL\n\n          -  Creatine clearance greater than 60 mL/min\n\n        Pulmonary:\n\n          -  DLCO at least 60%\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception during and for 2 months after study\n\n          -  No other concurrent active malignancies\n\n          -  Prior malignancies presumed to be cured allowed\n\n          -  No other concurrent uncontrolled severe medical problem that would preclude study\n             participation\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  At least 6 months since prior adjuvant chemotherapy without disease recurrence\n\n          -  No more than 1 prior chemotherapy regimen for metastatic disease\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  Prior adjuvant radiotherapy allowed\n\n          -  No prior radiotherapy to more than 25% of total bone marrow\n\n        Surgery:\n\n          -  Not specified\n\n        Other:\n\n          -  No other prior therapy for advanced disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "13", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 5, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005981", 
            "org_study_id": "CWRU1298", 
            "secondary_id": [
                "U01CA063200", 
                "P30CA043703", 
                "CWRU-1298", 
                "NCI-89"
            ]
        }, 
        "intervention": [
            {
                "description": "Patients receive O6-benzylguanine (BG) IV over 1 hour. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity.", 
                "intervention_name": "O6-benzylguanine", 
                "intervention_type": "Drug"
            }, 
            {
                "description": "Carmustine IV over 1 hour (beginning 1 hour after completion of BG infusion) on day 1. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity.", 
                "intervention_name": "carmustine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carmustine", 
                "O(6)-benzylguanine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "stage IV colon cancer", 
            "stage IV rectal cancer", 
            "recurrent colon cancer", 
            "recurrent rectal cancer"
        ], 
        "lastchanged_date": "June 9, 2010", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/CWRU-1298"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Cleveland", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "44106-5065"
                }, 
                "name": "Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Trial of O6Benzylguanine and BCNU in Patients With Colon and Rectal Carcinoma", 
        "overall_official": {
            "affiliation": "Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center", 
            "last_name": "Smitha Krishnamurthi, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Determine the response rate of patients with metastatic colorectal carcinoma treated with O6-benzylguanine and carmustine.", 
            "safety_issue": "No", 
            "time_frame": "Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005981"
        }, 
        "responsible_party": {
            "name_title": "Smitha Krishnamurthi, MD", 
            "organization": "Ireland Cancer Center at University Hospitals Cancer Medical Center, Case Comprehensive Cancer Center"
        }, 
        "source": "Case Comprehensive Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Case Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2000", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2010"
    }, 
    "geocoordinates": {
        "Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center": "41.499 -81.695"
    }
}